MedTrace Logo

Florbetaben PET Imaging in PPA

NCT04720001 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2024-10-16

No results posted yet for this study

Summary

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

Conditions

  • Primary Progressive Aphasia
  • Alzheimer Disease

Interventions

DRUG

Florbetaben F18

A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection

DEVICE

PET

PET Scan for brain imaging

Sponsors & Collaborators

Principal Investigators

  • Emily Rogalski, Ph.D · University of Chicago

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-23
Primary Completion
2021-01-21
Completion
2021-02-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04720001 on ClinicalTrials.gov